Phosphatidylinositol (3,4,5)P3 interacts with SH2 domains and modulates PI 3-kinase association with tyrosine-phosphorylated proteins  by Rameh, Lucia E. et al.
Cell, Vol. 83, 821-830, December 1, 1995, Copyright 0 1995 by Cell Press 
Phosphatidylinositol (3,4,5)P3 Interacts with 
SH2 Domains and Modulates PI 3-Kinase 
Association with Tyrosine-Phosphorylated Proteins 
Lucia E. Rameh,* Ching-Shih Chen,t 
and Lewis C. Cantley’ 
*Department of Cell Biology 
Harvard Medical School 
and Division of Signal Transduction 
Beth Israel Hospital 
Boston, Massachusetts 02115 
tDivision of Medicinal Chemistry and Pharmaceutics 
College of Pharmacy 
University of Kentucky 
Lexington, Kentucky 40536 
Summary 
Src homology 2 (SHZ) domains on the regulatory sub- 
unit of phosphoinositide 3-kinase (PI 3-kinase) medi- 
ate its binding to specific tyrosine-phosphorylated 
proteins in stimulated cells. Using a pharmacological 
and genetic approach, we show that the amount of 
PI 3-kinase associated with tyrosine-phosphorylated 
proteins inversely correlates with the amount of PI 
I-kinase lipid products present in the cell. An explana- 
tion for this observation is provided by our finding 
that phosphatidylinositol (3,4,5)trisphosphate (Ptdlns 
[3,4,5]P3) binds directly and selectively to the SH2 do- 
mains of the 85 kDa subunit of PI 3-kinase and thereby 
blocks binding to tyrosine-phosphorylated proteins. 
The SH2 domain of pp60c*rc also specifically bound 
Ptdlns (3,4,5)P3, and the binding was competed by a 
phosphopeptide specific for the Src SH2 domain. 
These results indicate that production of Ptdlns 
(3,4,5)P3 at the membrane disrupts the binding of PI 
3-kinase to phosphoproteins. This lipid may also re- 
cruit other SHP-containing proteins to the membrane 
to initiate downstream signaling. 
Introduction 
Src homology 2 (SH2) domains are conserved sequences 
of approximately 100 amino acids that are able to bind 
tyrosine-phosphorylated proteins in a phosphorylation- 
dependent and sequence-specific manner. SH2 domain- 
containing proteins are often downstream targets of pro- 
tein-tyrosine kinases (PTKs) (Cantley et al., 1991; Pawson, 
1995). 
Phosphoinositide 3-kinase (PI 3-kinase) is an SH2- 
containing enzyme found associated with a variety of re- 
ceptor and nonreceptor PTKs. The enzyme is a hetero- 
dimer of a 110 kDa (~110) catalytic subunit and an 85 kDa 
(~85) regulatory subunit (Carpenter et al., 1990). It can 
phosphorylate the D3 position of phosphatidylinositol 
(Ptdlns), Ptdlns (4)phosphate (Ptdlns [4]P), or Ptdlns 
(45)bisphosphate (Ptdlns [4,5]P2) to produce Ptdlns (S)P, 
Ptdlns (3,4)P2, or Ptdlns (3,4,5)trisphosphate (Ptdlns 
[3,4,5]P3), respectively (Whitman et al., 1988; Auger et al., 
1989; Carpenter et al., 1990). The ~85 subunit is com- 
posed of a Bcr homology domain, an Src homology3(SH3) 
domain, two proline-rich regions, and two SH2 domains 
(Escobedo et al., 1991; Skolnik et al., 1991; Otsu et al., 
1991; Kapeller et al., 1994). Activation of this enzyme by 
extracellular factors involves its recruitment to the mem- 
brane, in many cases via SH2-phosphotyrosine (pTyr) in- 
teractions (Kapeller and Cantley, 1994). However, the 
growth factor requirement for PI 3-kinase activation can 
be circumvented by expressing a constitutively active form 
of this enzyme, constituted by the ~110 subunit bound to 
a truncated form of ~85 that contains only the interSH2 
region (iSH2) and lacks all the regulatory domains (Hu et 
al., 1995). 
In addition to PI 3-kinase, several other SHP-containing 
proteins are recruited to the receptor complex in response 
to stimulation, resulting in a wide range of biological re- 
sponses. Among the proteins that bind to the platelet- 
derived growth factor (PDGF) receptor, for instance, are 
pp60c-src, PI 3-kinase, Nck, GAP, Syp, and phospholipase 
CT (Pawson, 1995). The insulin receptor, on the other 
hand, has fewer SHP-binding sites than the PDGF receptor 
and is thought to bind only a few SH2containing proteins 
directly, including PI 3-kinase (Ruderman et al., 1990; 
Backer et al., 1992b). Nonetheless, the insulin receptor 
is able to activate other SH2containing proteins through 
the phosphorylation of adaptor proteins, including the in- 
sulin receptor substrates 1 and 2 (IRS-1 and IRS-2). Phos- 
phorylated IRS-l is able to interact with PI 3-kinase, Grb-2, 
Syp, and Nck (White and Kahn, 1994). 
Several studies suggest that the PI 3-kinase lipid prod- 
ucts, Ptdlns (3,4)P, and Ptdlns (3,4,5)P3, are important 
regulators of ceil proliferation (Cantley et al., 1991). They 
are undetectable in quiescent cells and appear within sec- 
onds after growth factor stimulation (Auger et al., 1989). 
Ptdlns (3)P levels, on the other hand, do not significantly 
change with cell stimulation. Furthermore, Ptdlns (3,4)P2 
and Ptdlns (3,4,5)P3 are elevated in cells transformed by 
v-abl, v-sfc, and polyoma middle T, and decreased levels 
of these lipids correlate with impaired cell transformation 
by mutated forms of these oncogenes (Fukui et al., 1991; 
Varticovski et al., 1991; Cantley et al., 1991; Ling et al., 
1992). None of the D3-phosphorylated phosphoinositides 
is a substrate for phospholipase C, indicating that these 
lipids are themselves second messengers rather than pre- 
cursors of inositol phosphate second messengers (Seru- 
nian et al., 1989). 
Until recently, most of the studies addressing the role 
of PI 3-kinase on cellular responses were undertaken by 
transfection of receptor PTKs carrying point mutationsthat 
eliminate the binding site for ~85 or by microinjection of 
SH2 domains or neutralizing anti-SH2 antibodies (Backer 
et al., 1992b; Fantl et al., 1992; Valius and Kazlauskas, 
1993; Jhun et al., 1994). These approaches prevent activa- 
tion of PI 3-kinase, but they provide little information about 
the direct targets of the lipid products. With the identifica- 
tion of the drugs wortmannin (Yano et al., 1993; Okada 
Cell 
822 
et al., 1994) and Ly294002 (Vlahos et al., 1994) as potent 
PI 3-kinase inhibitors, it is possible to complement these 
experiments by directly and acutely inhibiting the activity 
of PI 3-kinase in intact cells. 
While investigating the effect of these inhibitors, we 
made the surprising observation that inhibition of insulin- 
induced Ptdlns (3,4)P2 and Ptdlns (3,4,5)P3 formation cor- 
relates with increased association of PI 3-kinase protein 
with tyrosine-phosphorylated proteins. Investigation of 
this phenomenon led to the observation that Ptdlns 
(3,4,5)P3 directly binds to the SH2 domains of PI 3-kinase 
in competition with phosphoproteins. We also show that 
other SH2 domains can bind Ptdlns (3,4,5)P3, raising the 
possibility that some physiological responses of PI 3-kinase 
are mediated by SHP-containing proteins. 
Results 
PI 3-Kinase Inhibition by Wortmannin and Ly294002 
Stabilizes the Association of PI 3-Kinase with 
Tyrosine-Phosphorylated Proteins 
To test whether PI 3-kinase activation is important for insu- 
lin-induced association of PI 3-kinase with pTyr-containing 
proteins, we incubated CHO cells transfected with human 
insulin receptor (HIR cells) with the PI 3-kinase inhibitors 
Ly294002 or wortmannin for 15 min prior to insulin stimula- 
tion. In agreement with previous studies (Ruderman et al., 
1990) insulin caused an increase in the amount of the 85 
kDa subunit of PI 3-kinase that can be precipitated with 
anti-pTyr antibody in the absence of PI 3-kinase inhibitors 
(Figure 1 a). Surprisingly, we observed afurther increase in 
the amount of ~85 present in anti-pTyr immunoprecipitates 
from insulin-stimulated cells that had been treated with 
either Ly294002 (500/o-80% increase) or wortmannin 
(1500/o-250% increase). The greater effect of wortmannin 
compared with Ly294002 is consistent with wortman- 
nin being more effective than Ly294002 in blocking the 
insulin-dependent stimulation of Ptdlns (3,4,5)P3 produc- 
tion at the concentrations used (see below). While wort- 
mannin inhibition of PI 3-kinase is irreversible, Ly294002 
binding to PI 3-kinase is reversible and can be washed 
away during the immunoprecipitation procedures. There- 
fore, the amount of PI 3-kinase activity present in the anti- 
pTyr immunoprecipitates from Ly294002-treated cells re- 
flects the amount of ~85 present (Figures 1 a and 1 c, lane 
3). On the other hand, the anti-pTyr immunoprecipitates 
from the wortmannin-treated cells show very little PI 
3-kinase activity, despite the fact that they contain more 
~85 protein (Figures la and lc, lane 4). 
The effects of Ly294002 and wortmannin on the associ- 
ation of PI 3-kinase with tyrosine-phosphorylated proteins 
were also investigated by immunoprecipitating with an 
anti-p85 antibody. This antibody has been shown to immu- 
noprecipitate tyrosine-phosphorylated IRS-l (185 kDa) 
and, to a lesser extent, tyrosine-phosphorylated insulin 
receptor (95 kDa) in response to insulin (Backer et al., 
1992a; Kelly and Ruderman, 1993). Treatment of HIR cells 
with wortmannin or Ly294002 enhanced the amount of PI 
3-kinase-associated ~185 (Figure 1 d) and p95 (data not 
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Figure 1. p85 Association with Tyrosine-Phosphorylated Proteins Is 
Stabilized by Ly294002 and Wortmannin Treatment In Vivo 
Serum-starved HIR cells were pretreated with DMSO (minus), 10 PM 
Ly29402 (Ly), or 100 nM wortmannin (W) and stimulated with 100 
nM insulin (I) for 1 min. Cell lysates were prepared as described and 
precipitated with anti-pTyr (a-c) or anti-p85 antibodies (d and e). Pro- 
teins present in the immune complexes (a, b, d, and e) or in the cell 
lysates (9 were separated by 7.5% SDS-polyacrylamide gel electro- 
phoresis (SDS-PAGE) and blotted sequentially with anti-p85 antibody 
(a and e) and then anti-pTyr antibody (b, d, and 9. The anti-pTyr precipi- 
tates were also assayed for PI 3-kinase activity(c). The insulin receptor 
(IR), IRS-l, and p85 bands are indicated. The data presented are 
representative of more than three experiments. Error bars in (c) repre- 
sent the standard error from three experiments. 
shown) detectable by anti-pTyr antibodies. Ly294002 and 
wortmannin did not significantly affect the total amount of 
p85 precipitated or the amount of tyrosine phosphorylation 
in total cell lysates and anti-pTyr immunoprecipitates (Fig- 
ures le, If, and 1 b). In agreement with previous results, 
very little pTyr was detected at the position of ~85 (data 
not shown). These results all indicate that inhibition of PI 
3-kinase increases its association with tyrosine-phosphor- 
ylated proteins. 
To understand better the effect of these PI 3-kinase 
inhibitors, we performed a time course of insulin stimula- 
tion in cells pretreated with dimethyl sulfoxide (DMSO), 
Ly294002, or wortmannin. Increased ~85 association with 
tyrosine-phosphorylated proteins in cells pretreated with 
Ly294002 (data not shown) and wortmannin (Figure 2a) 
was observed as early as 1 min after insulin stimulation. 
Acorrelation between PI 3-kinase inhibition and increased 
~85 association with tyrosine-phosphorylated proteins 
was observed when cells were treated with different doses 
of wortmannin (Figure 2b). The effect of wortmannin was 
observed at concentrations as low as 1 nM. Lipid analysis 
revealed that insulin-stimulated in vivo production of 
Ptdlns (3,4)P2 (Figure 2c) and Ptdlns (3,4,5)P3 (Figure 2d) 
was almost totally abolished by wortmannin treatment and 
only partially blocked by Ly294002 at the concentrations 
used in the experiments presented in Figures 1 and 2a. 
Thus, decreasing the amount of Ptdlns (3,4)P~ and Ptdlns 
(3,4,5)P3 correlates with an increase in the association of 
p85 with tyrosine-phosphorylated proteins. 
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Figure 2. Increased p85 Association with Tyrosine-Phosphorylated 
Proteins Correlates with PI 3-Kinase Inhibition In Vivo 
(a) Serum-starved HIR cells were pretreated with DMSO carrier (cir- 
cles) or 100 nM wortmannin (triangles) for 15 min, stimulated with 100 
nM insulin at time zero, and lysed in NP-40 buffer at the indicated 
times. Lysates were precipitated with anti-pTyr antibody, blotted for 
~85, and quantified as described. The standard errors (of three experi- 
ments)forthe 1 min insulin treatmentwere f 13%(control)and f 10% 
(wortmannin). The data presented are representative of three experi- 
ments. 
(b) Serum-starved HIR cells were treated with different concentrations 
of wortmannin prior to insulin stimulation (100 nM). After 5 min, cells 
were lysed in NP-40 buffer, and the lysates were precipitated with 
anti-pTyr antibody. The precipitates ware assayed for PI 3-kinase activ- 
ity (closed circles) and blotted for p85 protein (open circles) as in Figure 
1. PI 3-kinase-specific activity was calculated by dividing the relative 
activity by the relative amount of p85 protein. Error bars indicate the 
range from two experiments. 
(C and d) Serum-starved HIR ceils were labeled with =P inorganic 
phosphate for 4 hr, treated with DMSO (circles), 10 NM Ly294002 
(squares), or 100 nM wortmannin (triangles), and then stimulated with 
insulin (time zero). Cells were lysed at the indicated time, and lipids 
were extracted, deacylated, and analyzed by high pressure liquid chro- 
matography (HPLC) as described. The peaks corresponding to Ptdlns 
(3,4)P~ (c) and Ptdlns (3,4,5)P3 (d) were quantified and normalized to 
the total amount of 32P label in Ptdlns (4)P plus Ptdlns (4,5)Pz. The 
data presented are representative of three experiments. 
Overexpression of a Constitutively Active Form of PI 
3-Kinase Reduces the Amount of PI 3-Kinase 
Associated with Tyrosine-Phosphorylated Proteins 
To confirm the results obtained with PI 3-kinase inhibitors, 
we transiently transfected HIR cells with a Myc-tagged 
version of p85 or the iSH2 region of p85 that binds and 
activates ~110 (Klippel et al., 1993). lmmunoprecipitation 
with anti-Myc antibody has shown that the iSH2 is able 
to associate with endogenous ~110 and cause constitu- 
tive activation of the PI 3-kinase activity (6. Duckworth, 
A. Toker, and L. C. C., unpublished data). The Ptdlns 
(3,4,5)P3 levels in the iSH2-transfected cells were compa- 
plasm id: CMV CMV-~85 CMV-iSH2 
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Figure 3. The Amount of p85 Associated with Tyrosine- 
Phosphorylated Protein Complex Is Decreased by Overexpression of 
the iSH2 Region of p85 
HIR cells were transiently transfected with control plasmid (CMV) or 
plasmids expressing the full-length p85 (CMV-~85) or iSH2 (CMV- 
iSH2) under the CMV promoter. Cells were or were not stimulated 
with 100 nM insulin for 5 min and were lysed in NP-40 buffer. Total 
cell lysates (a and c) and anti-pTyr precipitates (b) were separated by 
7.5% SDS-PAGE and blotted using anti-p85 (a and b) or anti-pTyr (c) 
antibodies. Total protein concentration of the lysates from CMV-p85- 
and CMV-iSH2-transfected cells were, respectively, 70% and 80% of 
the CMV-transfected cells. The ~85, iSH2, and insulin receptor (IR) 
bands are indicated on the left. The data shown are representative 
of two experiments. (d) shows the percentage of PI 3-kinase activity 
present in anti-pTyr precipitates from two separate experiments, nor- 
malized by the activity present in insulin-stimulated cells transfected 
with control vector. Error bars indicate the range of the two experi- 
ments. 
rable with those at the peak of PDGF stimulation of the 
parental cells (data not shown). Transient expression of 
these cDNAs in HIR cells resulted in protein levels that 
were 5- to lo-fold higher than endogenous ~85, as ana- 
lyzed by blotting total cell lysates from these cells with 
anti-p85 antibody (Figure 3a). 
Expression of the iSH2domain dramatically reduced the 
amount of p85 that associates with tyrosine-phosphorylated 
proteins in response to insulin stimulation (compare lanes 
2 and 8 in Figure 3b). Cells overexpressing full-length ~85, 
on the other hand, had increased levels of basal and insu- 
lin-stimulated anti-pTyr-associated p85 (Figure 3b), even 
though the levels of tyrosine-phosphorylated insulin recep- 
tor (Figure 3c) and IRS-1 (data not shown) were similar to 
those in cells transfected with control vector. Overexpres- 
sion of iSH2 also decreased the amount of insulin- 
stimulated PI 3-kinase activity in anti-pTyr immunoprecipi- 
tates (Figure 3d). In agreement with previous observations 
that excess p85 competes with endogenous p85/pllO for 
binding to tyrosine-phosphorylated proteins, overexpres- 
sion of p85 reduced the PI 3-kinase activity in antipTyr immu- 
noprecipitates from insulin-stimulated cells (Figure 3d). 
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Therefore, expression of a constitutively active form of 
PI 3-kinase decreases the amount of pTyr-p85 com- 
plexes, while overexpression of ~85 (dominant negative) 
increases the amount of pTyr-p85 complexes. 
Together, these results suggest that PI 3-kinase lipid 
products interfere with the interaction between tyrosine- 
phosphorylated proteins and the ~85 subunit of PI 3-kinase. 
Since SH2 domains mediate this interaction, we explored 
the possibility that phosphoinositides directly associate 
with the SH2 domains of ~85 to cause release from phos- 
phoproteins. 
PI 3-Kinase Lipid Products Bind to the SH2 
Domains of ~85 
To test whether PI 3-kinase lipid products associate 
directly with ~85, we incubated a glutathione S-trans- 
ferase (GST)-~85 fusion protein immobilized on glutathi- 
one-Sepharose beads with phosphatidylserine lipid vesi- 
cles containing [3ZP]Ptdlns (3)P, [32P]Ptdlns (3,4)P2, and 
[3*P]Ptdlns (3,4,5)P3 in the presence of 0.02% NP-40. Re- 
combinant proteins from different domains of ~8.5 as well 
as the whole protein were tested. The percentage of Ptdlns 
(3,4,5)P3 that remained associated with the various GST 
beads after a fast wash with 0.5% NP-40 is plotted in Fig- 
ure 4a. SH2-containing GST beads retained a substantial 
portion of the original [32P]Ptdlns (3,4,5)P3, about 6% for 
~85 and 13% for its carboxy-terminal SH2 domain. In con- 
trast, the SH3 domain and GST alone failed to bind a 
significant amount of lipid under these conditions. Phenyl 
phosphate (20 mM) competed for [32P]Ptdlns (3,4,5)P3 
binding to the amino- and carboxy-terminal SH2 domains, 
but did not affect the low level of binding to GST or GST- 
SH3 and only partially blocked binding to full-length ~85 
(discussed further below). 
To investigate whether the ability to bind DS-phos- 
phorylated lipids is a feature shared by other SH2 do- 
mains, we performed the lipid binding assay using GST 
fusion proteins containing SH2 domains from different pro- 
teins (Figure 4a). Src SH2 was able to bind 10% of the 
Ptdlns (3,4,5)P3 from the original lipid mixture, and this 
interaction was almost totally blocked by phenyl phos- 
phate. Abl SH2 and Lck SH2 were capable of binding to 
lipids better than the control GST and GST-SH3 domain. 
As with other SH2 domains, phenyl phosphate blocked 
this lipid binding. 
A comparison between the phenyl phosphate-inhibit- 
able [32P]Ptdlns (3,4,5)P3 binding and the phenyl phos- 
phate-inhibitable [32P]Ptdlns (3)P binding (data not shown) 
to the carboxy-terminal SH2 domain (using a phosphorim- 
ager to quantitate the 32P) revealed a 3-to 5-fold selection 
for Ptdlns (3,4,5)P3 (after normalizing for the abundance 
of the3*P-labeled lipids in the starting mixture). The binding 
was not affected by the presence or absence of physiologi- 
cal concentrations of divalent cations (1 mM MgZ+ and 1 
pM Ca2+; data not shown). 
The relative abilities of the various SH2 domains to bind 
[32P]phos6hoinositides was in agreement with their rela- 
tive abilities to bind tyrosine-phosphorylated proteins from 
insulin-stimulated cells (Figure 4b), except for Abl and Lck 
b 
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Figure 4. Phosphoinositide Products of Pl9Kinase Bind to SH2 Do- 
mains 
(a) Binding of Ptdlns (3,4,5)P3 to different domains of p85 or to SH2 
domains of different proteins. GST fusion protein beads were incu- 
bated with phosphatidylserinevesicles(ll8 ~M)containing~~P-labeled 
Ptdlns (3,4,5)P3 (0.1 wM), Ptdlns (3,4)P2 (0.03 PM), and Ptdlns (3)P 
(0.03 PM) in the presence or absence of 20 mM phenyl phosphate 
(see Experimental Procedures). The beads were washed with 0.5% 
NP-40, and the lipids that remained associated were extracted with 
chloroform:methanol and separated on a thin-layer chromatography 
plate. The amount of radioactivity present in the Ptdlns (3,4,5)P3 spot 
was determined and plotted as a percentage of the total Ptdlns 
(3,4,5)P, present in the original lipid mixture. The data shown are 
representative of more than three experiments. CT-SHP, carboxy- 
terminal SH2 domain: NT-SHP, amino-terminal SH2 domain. 
(b) Binding of tyrosine-phosphorylated proteins to various SH2 do- 
mains. GST fusion protein beads were incubated with lysates from 
insulin-stimulated HIR cells at 4°C for 1 hr. Beads were washed as 
described, and the proteins were denatured, separated by 7.5% SDS- 
PAGE, and blotted with anti-pTyr antibodies. The insulin receptor (IR) 
and IRS-l bands are indicated. 
SH2 domains, which bound lipids more weakly than pro- 
teins. These results indicate that phosphoinositide prod- 
ucts of PI 3-kinase directly bind to SH2 domains. 
SH2 Domains Preferentially Bind Ptdlns (3,4,5)P3 
The ability of the DS-phosphorylated phosphoinositides to 
bind to the Src SH2 and ~85 carboxy-terminal SH2 do- 
mains was not affected when the assay was performed 
using phosphatidylserine vesicles containing different lip- 
ids, such as phosphatidylcholine, phosphatidylethanolam- 
ine, phosphatidic acid, or cholesterol, in addition to Ptdlns 
(3,4,5)P3 in a 1O:l molar ratio. These results indicate that 
SH2 domain binding to lipids is restricted to the phospho- 
inositide family. To determine whether SH2 domains are 
able to associate preferentially with a specific phosphoino- 
sitide, we incubated vesicles containing a mixture of all 
the [3ZP]phosphoinositide products of PI 3-kinase, Ptdlns 
4-kinase, and Ptdlns (4)P 5-kinase with different GST- 
SH2 domains in 0.02% NP-40 for 1.5 hr and then washed 
them with 0.5% NP-40. The relative amount of each lipid 
in the pellet was divided by the amount in the starting 
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Figure 5. Selectivity of SH2 Domains for Ptdlns (3,4,5)P3 
A mixture of sonicated [3ZP]phosphoinositides was incubated with vari- 
ous GST-SHP beads, as described in Experimental Procedures. The 
lipids that remained associated with SH2 domains after washing the 
beads were extracted, deacylated, and analyzed by HPLC. The peaks 
corresponding to each lipid were quantified, and the data were normal- 
ized as described in Experimental Procedures. The normalization was 
such that if all lipids bound equally well, then each would have a 
selectivity of 1. Shown is a representative result from three similar 
experiments. 
mixture to provide an indication of the selectivity of each 
SH2 domain for individual phosphoinositides(Figure5). All 
three SH2 domains preferentially bound Ptdlns (3,4,5)P3. 
Full-length p85 was less selective for Ptdlns (3,4,5)P3, 
probably because of the additional site in the interSH2 
of ~8.5 that binds Ptdlns (4)P and Ptdlns (4,5)P2 (End et 
al., 1993). Of all the SH2 domains investigated, the Abl 
SH2 domain had the lowest affinity (Figure 4) and the least 
selectivity (1.8-fold selection for Ptdlns [3,4,5]P3 over other 
phosphoinositides; data not shown). No detectable Ptdlns 
(3,4,5)P3 was found associated with either GST alone or 
the GST-p85 SH3 in these experiments (data not shown). 
Ptdlns (3,4,5)P3 Association with the Src SH2 Domain 
Is Competed by an SHP-Specific Phosphotyrosine 
Peptide, but Is Not Affected by Mutation of an 
Arginine Residue in the pTyr-Binding Pocket 
To characterize further the interaction between SH2 do- 
mains and Ptdlns (3,4,5)P3, we tested whether pTyr- 
containing peptides that specifically bind to the pTyr 
pocket of the Src SH2 domain can compete with the lipid. 
Asseen in Figures6aand6b, phosphopeptidescontaining 
the sequence pYEEl competed at 10 pM with Ptdlns 
Figure 6. Ptdlns (3,4,5)P3 Interaction with Src SH2 Competes with 
pTyr Binding, but Does Not Require the Arginine of the FLVR Se- 
quence 
(a)Ptdlns (3,4,5)P3 binding to GST-Src SH2 beads in the presence of 
1 uM (closed bars), 10 uM (hatched bars), or 100 uM (open bars) of 
the peptides pYEEl (lanes l-3), YEEI (lanes 4-6) or pYMPM (lanes 
7-9) was performed and analyzed as described for Figure 4a (see 
Experimental Procedures for complete peptide sequences). The re- 
sults were plotted as a percentage of the Ptdlns (3,4,5)P3 bound to the 
beads in the presence of 1 uM pYEEl peptide (which is not significantly 
different from the content in the absence of peptide). Error bars indicate 
standard error from three experiments (lanes 1,2,3, and 8) or the range 
from two experiments (lanes 4, 5, 6, 7, and 9). 
(b) Insulin receptor binding to the Src SH2 domain in the presence of 
1, IO, or 100 uM of the peptide pYEEI. GST-Src SH2 beads were 
incubated with lysates from insulin-stimulated HIR cells, as described, 
in the presence of different concentrations of peptide, and the relative 
amount of phosphorylated insulin receptor bound was determined as 
described in Figure 4b. 
(c) Ptdlns (3,4,5)P3 binding to wild-type (WT) Src SH2 domain or mu- 
tants Arg-178+Lys (R-K) and Arg-178-Gln (R-Q) in the presence or 
absence of 20 mM phenyl phosphate was analyzed as described for 
Figure 4a. A thin-layer chromatographic showing the Ptdlns (3,4,5)P3 
(PIP,) spot is presented (which isrepresentative of three experiments). 
(d) Anti-pTyr blot showing binding of wild-type Src SH2 domain and 
mutants to tyrosine-phosphorylated proteins from insulin-stimulated 
cells. Results were obtained as described for Figure 4b. The migration 
positions of IRS-l and molecular mass markers are indicated on the 
right. 
(3,4,5)P~, as well as with pTyr-containing proteins, for Src 
SH2 binding. A phosphopeptide with lower affinity for the 
Src SH2 domain (pYMPM; Songyang et al., 1993) com- 
peted at higher concentrations, while an unphosphory- 
lated peptide containing the sequence YEEI did not signifi- 
cantly affect the lipid-SH2 interaction at concentrations 
up to 100 pM. Consistent with previous observations that 
a pYMPM-containing peptide binds specifically to the SH2 
domains of p85 (Fantl et al., 1992; Songyang et al., 1993), 
this peptide competed 50% of the phenyl phosphate-sen- 
sitive lipid binding to the ~85 amino-terminal SH2 at 10 PM, 
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while at this concentration no competition was observed 
using the pYEEl peptide (data not shown). Thus, phospho- 
peptide competition for lipid binding occurs at the well- 
characterized phosphopeptide-binding sites. 
Binding of pTyr-containing peptides to SH2 domains is 
known to involve the arginine residue present in the FLVR 
sequence that is conserved among these domains. To 
determine whether lipid binding to SH2 domains also in- 
volves this arginine residue, GST-Src SH2 domain mu- 
tants were tested for their ability to bind the 3ZP-labeled 
PI 3-kinase lipid products. Substitution of the Arg-178 with 
lysine or glutamine did not decrease the ability of this SH2 
domain to bind Ptdlns (3,4,5)P3 (Figure 6~). However, con- 
sistent with the requirement of Arg-178 for pTyr binding, 
the ability of phenyl phosphate to compete for the lipid 
interaction was almost completely abolished by the Arg- 
178+Lys mutation and was totally eliminated by the Arg- 
178*Gln mutation. As expected, the Arg-178+Lys mutant 
(in which the positive charge of the residue is maintained) 
was impaired in its capacity to bind tyrosine-phosphoryl- 
ated proteins, and the Arg-178+Gln mutant (in which the 
positive charge is eliminated) was completely defective in 
pTyr-binding function (Figure 6d). These results indicate 
that, while pTyr binding and Ptdlns (3,4,5)P3 binding are 
competitive, they do not utilize all the same positively 
charged residues of the pTyr-binding pocket. These re- 
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Figure 7. Ptdlns (3,4,5)P3 Blocks ~85 Carboxy-Terminal SH2 Binding 
to Phosphorylated Insulin Receptor 
GST beads containing the carboxy-terminal SH2 domain of p85 were 
incubated with different concentrations of sonicated Ptdlns (4,5)P2 (cir- 
cles) or chemically synthesized Di& Ptdlns (3,4,5)P3 (Liscovitch et 
al., 1994)(squares), asdescribed. Lysatesfrom insulin-stimulated HIR 
cells were added so that the final concentration of NP-40 was 0.5%. 
After 10 min, the beads were washed and the proteins associated 
were analyzed by anti-pTyr blotting. The scanned image of the insulin 
receptor band was quantified as described. The results are expressed 
as a percentage of the total amount of insulin receptor associated with 
SH2 beads in the absence of lipids. Error bars represent the range 
from duplicate samples. 
suits also confirm that the phenyl phosphate competition 
for lipid binding occurs via the pTyr pocket. 
Ptdlns (3,4,5)P3 Blocks In Vitro Binding of ~85 
Carboxy-Terminal SH2 to Phosphorylated 
Insulin Receptor 
We also investigated whether Ptdlns (3,4,5)P3 and Ptdlns 
(4,5)P~ could interfere with the ability of SH2 domains to 
bind pTyr-containing proteins from a cell lysate. Figure 7 
shows that synthetic dipalmitoyl Ptdlns (3,4,5)P3 (pre- 
sented as NP-40-mixed micelles) blocks the binding of 
GST-~85 carboxy-terminal SH2 to the insulin receptor 
with a 50% maximal effect at approximately 5 PM (Ptdlns 
[3,4,5]P~ also inhibited ~85 carboxy-terminal SH2 binding 
to IRS-1 by 50% at 5 PM; data not shown). In agreement 
with the results in Figure 5, Ptdlns (4,5)P2 micelles were 
less effective at blocking binding. Similar results were ob- 
tained when Ptdlns (3,4,5)P3 was presented in phosphati- 
dylserine vesicles (data not shown). We also investigated 
the ability of inositol polyphosphates to block the Src SH2 
domain binding to insulin receptor and found that inositol 
(1,3,4,5)P,, the head group of Ptdlns (3,4,5)P3, had a much 
lower affinity than Ptdlns (3,4,5)P3: inositol (1 ,3,4,5)P4 in- 
hibited 29% of the insulin receptor binding at 1 mM con- 
centration, while Ptdlns (3,4,5)P3 inhibited 90% at 80 KM. 
Nevertheless, it did bind better than inositol (1 ,4,5)P3, the 
head group of Ptdlns (4,5)P2, which inhibited only 14% of 
the insulin receptor binding at 1 mM concentration (data 
not shown). These results indicate that the diacylglycerol 
component of the lipid provides additional affinity. 
Discussion 
The data presented in this paper demonstrate a novel pro- 
tein-lipid interaction between SH2 domains and a phos- 
phoinositide product of PI 3-kinase, Ptdlns (3,4,5)P3. The 
~85 amino-terminal and carboxy-terminal SH2 domains 
and the Src SH2 domain had specificity for binding Ptdlns 
(3,4,5)P3 over other phosphoinositides. The Lck and Abl 
SH2 domains also had significant, although weaker, bind- 
ing to Ptdlns (3,4,5)P3. The ability of phenyl phosphate 
and tyrosine-phosphorylated peptides to block the Ptdlns 
(3,4,5)P3-SH2 interaction indicates that lipid binding and 
phosphopeptide binding are mutually exclusive. The argi- 
nine at position 178 of the Src SH2 domain is required for 
pTyr binding, but not for Ptdlns (3,4,5)P3 binding, indicat- 
ing that lipid and phosphoprotein interactions with SH2 
domains are not coordinated by the same residues inside 
the pocket. 
Evidence that PI 3-kinase lipid products compete with 
pTyr-containing proteins for binding to the p85 subunit 
of PI 3-kinase in vivo is provided by experiments with PI 
3-kinase inhibitors and by overexpression of dominant 
positive PI 3-kinase. Blocking the production of Ptdlns 
(3,4,5)P3 with wortmannin or Ly294002 enhances pTyr- 
~85 protein interactions, while expression of constitutively 
active PI 3-kinase reduces pTyr-p85 protein interactions. 
These results suggest some interesting models for the 
involvement of PI 3-kinase in signal transduction. It is likely 
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that local concentrations of Ptdlns (3,4,5)P3 will be enough 
to bind to the SH2 domain of ~85 since the lipid is synthe- 
sized locally by the catalytic subunit of this protein. This 
could be an effective mechanism of dissociating PI 3kinase 
from tyrosine-phosphorylated proteins once the lipid prod- 
uct has reached an optimal level, providing a negative 
feedback control mechanism. However, it is also possible 
that the Ptdlns (3,4,5)P3 recruits a subgroup of SH2- 
containing proteins to specific compartments of the cell. 
For example, binding of Grb-2 to Ptdlns (3,4,5)P3 could 
be an alternative mechanism to binding of Grb-2 to recep- 
tors for recruiting the Grb9-SOS complex to the plasma 
membrane. Ptdlns (3,4,5)P3 binding to the SH2 domain 
of p~60~-~~ could also be important for the localization or 
activation of this enzyme (or for both). Experiments to test 
these ideas are in progress. 
To date, PI 3-kinase has been implicated in a plethora 
of cellular responses, including mitogenesis (Whitman et 
al., 1985; Kaplan et al., 1987; Coughlin et al., 1989; Cant- 
ley et al., 1991), chemotaxis (Kundra et al., 1994; Wenn- 
Strom et al., 1994), membrane ruffling (Wennstrom et al., 
1994), activation of p7OS6 kinase (Chung et al., 1994) 
insulin-dependent Glut4 recruitment (Cheatham et al., 
1994; Clarke et al., 1994), glycogen synthesis (Cross et 
al., 1994; Welsh et al., 1994), activation of integrins in 
platelets (Kovacsovics et al., 1995), histamine release 
(Yano et al., 1993), receptor down-regulation (Joly et al., 
1994), and blocking apoptosis (Yao and Cooper, 1995). In 
addition, the yeast homolog of PI 3-kinase, Vps34p (which 
produces Ptdlns [3]P but not Ptdlns [3,4]P2 or Ptdlns 
[3,4,5]P3), is required for trafficking of proteins from the 
Golgi to the vacuole (Herman and Emr, 1990; Hiles et al., 
1992). It seems unlikely that a single target for the D3 
phosphoinositides mediates these diverse responses. 
Thus, it is an attractive idea that various SH2 domains 
bind to specific D3 phosphoinositides to mediate distinct 
responses. 
The fact that Ptdlns (3,4)Pn and Ptdlns (3,4,5)P3 are 
normally undetectable in quiescent cells and appear within 
seconds to minutes of stimulation with various growth fac- 
tors or hormones is consistent with these molecules acting 
as second messengers (Auger et al., 1989). In addition to 
the evidence presented here that SH2 domains bind to 
Ptdlns (3,4,5)P3, we have previously shown that both 
Ptdlns (3,4)P2 and Ptdlns (3,4,5)P3 activate protein kinase 
C types E, n, and 6 (Toker et al., 1994). Activation of native 
protein kinase C-c (Nakanishi et al., 1993), but not recom- 
binant protein kinase C-c (Toker et al., 1994) has also 
been reported. Interestingly, Ptdlns (3,4)P2 is more effec- 
tive than Ptdlns (3,4,5)P3 in activating the Ca2+- 
independent protein kinase C isoforms (Tokeret al., 1994), 
while Ptdlns (3,4,5)P3 is more effective than Ptdlns (3,4)P2 
in binding to the Src and ~85 SH2 domains (Figure 5). 
Recently, Ptdlns (3)P was implicated in the activation of 
the Akt Ser/Thr protein kinase via a Plekstrin homology 
domain (Franke et al., 1995). These results raise the possi- 
bility that the different lipid products of PI 3-kinase prefer- 
entially activate different targets in the cell and begin to 
provide a framework for understanding the diverse cellular 
responses in which PI 3-kinase has been implicated. 
Experimental Procedures 
Cell Culture 
CHO cells transfected with wild-type HIR (White et al., 1988) were 
cultured in RPM1 medium containing 10% FCS and 0.4 mglml 6418 
until they reached 80% confluence. Cells were serum starved in RPM1 
containing 0.5% bovine serum albumin (BSA) for 48 hr. For the PI 
3kinase inhibitor experiments, cells were treated with DMSO carrier, 
10 pM Ly294002 (Lilly) in DMSO, or 100 nM wortmannin (Sigma) in 
DMSO for 15 min prior to insulin stimulation. 
Transient Transfection 
HIR cells were cultured in 100 mm dishes until they reached 70% 
confluence. We used 8 ug of plasmid DNA(pRC [lnvitrogen] containing 
the cytomegalovirus [CMV] promoter, CMV-~85, or CMV-iSH2) and 
48 ul of lipofectamine reagent (GIBCO BRL) to transfect each plate 
in the absence of serum. After 18 hr, the medium was replaced by 
RPMI-O.5% BSA. Approximately 45 hr after the beginning of the trans- 
fection, the cells were or were not stimulated with 100 nM insulin 
and lysed as described below. The CMV-iSH2 plasmid is a construct 
containing the Myc tag sequence fused to the carboxy-terminal se- 
quence of the iSH2 region (amino acids 428-678) of the human p85 
cDNA, cloned into a vector containing the CMV promoter. The CMV- 
p85 plasmid was constructed by fusion of the Myc tag sequence to 
the amino-terminal sequence of the bovine p85 cDNA and cloning into 
a vector containing the CMV promoter. 
lmmunoprecipitation and lmmunoblot 
Cells were lysed in 1 ml of NP-40 lysis buffer (137 mM NaCI, 20 mM 
Tris-HCI [pH 7.51, 1 mM MgC&, 1 mM CaC12, 10% glycerol, 1% NP-40) 
containing protease inhibitors (I ttglml leupeptin, 1 uglml aprotinin, 
1 uglml pepstatin, and 1 mM PMSF) and phosphatase inhibitor (1 mM 
sodium vanadate). Cells were scraped after rocking for 15 min at 4OC, 
and the lysates were cleared by centrifugation at 15,000 rpm for 10 
min. Variations in the total protein concentration of different cell ly- 
sates (measured using the Bio-Rad protein assay reagent) were less 
than 7%. 
Antibody and protein A-Sepharose were added to lysates, and the 
mixture was incubated at 4°C for 3 hr. lmmunoprecipitates were 
washed three times with PBS-l% NP-40, twice with 0.5 M LiCI, 0.1 
M Tris-HCI (pH 7.5), and twice with IO mM Tris-HCI (pH 7.5) 100 mM 
NaCI, 1 mM EDTA and were assayed for PI bkinase activity, using 
Ptdlns (4,5)P2 as a substrate as previously described (Serunian et al., 
1991) or were denatured in Laemmli’s buffer for 10 min at 100°C. 
Proteins present in the immunoprecipitates were separated by 
7.5% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and trans- 
ferred to a nitrocellulose membrane. After blocking with TBS (20 mM 
Tris-HCI ]pH 8.01, 137 mM NaCI) containing 5% lowfat milk, the mem- 
branes were incubated with primary antibody for 1 hr in TBS-0.05% 
Tween 20 for 45 min with secondary antibody conjugated with HRP 
and developed using the chemiluminescence detection system (Du- 
Pont). The anti-p85 antibody was obtained from UBI, and the anti-pTyr 
antibody (4GlO) was a gift from Dr. T. Roberts. The scanned images 
of autoradiograms were quantified using the NIH image program. For 
the kinetics experiments (Figure Za), the amount of ~85 was calculated 
based on a p85 standard curve obtained from immunoblots of p85 
containing serial dilutions of the protein. 
In Vivo Labeling of Lipids and HPLC Analyses 
HIR cells were labeled with 0.5 mCi/ml of inorganic [-PIphosphate 
for 4 hr. After being treated with inhibitors as described above, cells 
were stimulated with insulin for 2.5, 5, IO, or 20 min at 37‘C. One 
100 mm plate was used for each timepoint. Cells were harvested with 
800 ~1 of methanol, 1 M HCI (1:l). Lipids were extracted with 400 
~1 of chloroform, deacylated, and analyzed by high pressure liquid 
chromatography (HPLC) on a SAX column, as described previously 
(Serunian et al., 1991). The peaks corresponding to the deacylated 
products of Ptdlns (3,4)P~ and Ptdlns (3,4,5)P3 were identified with the 
use of 3H standards, and the radioactivity present in each peak was 
quantified with the use of an on-line radiomatic detector (Packard) and 
normalized to the total amount of =P label in Ptdlns (4)P plus Ptdlns 
(4,5)P~. For the experiment shown in Figures 2c and 2d, the peak 
amounts of [“PlPtdlns (3,4)Pz and ]32P]Ptdlns (3,4,5)PJ in the insulin- 
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stimulated cells ware approximately 0.1% and 0.5%, respectively, of 
the total [32P]phosphoinositides in the cell. 
GST Fusion Proteins 
pGEX vectors containing the cDNA sequences encoding the SH2 do- 
mains, the p85 protein, p85 carboxy-terminal SH2, p85 amino-terminal 
SH2 (Yoakim et al., 1992) or p85 SH3 (Kapeller et al., 1994) were 
expressed in Escherichia coli as GST fusion proteins by isopropyt+D- 
thiogalactopyranoside induction. Bacterial lysates (prepared as de- 
scribed in Sambrook et al. [1989]) were incubated with glutathione- 
Sepharose beads for 2 hr at 4°C and washed several times with 30 
mM HEPES (pH 7.0), 100 mM NaCI, 1 mM EDTA (HNE) containing 
0.5% NP-40, followed by HNE. 
Protein Binding Assay 
HIR cells were stimulated with insulin for 10 min and lysed in 1% 
NP-40-HNE buffer. Lysateswere centrifuged for 10 min at 14,000 rpm, 
and supernatants were incubated with different GST-Sepharose beads 
at4’Cfor 1 hr. Beadswerewashedasdescribedfortheimmunoprecip 
itation procedures, resuspended in an equal volume of 2 x Laemmli’s 
buffer, and incubated for 10 min at 100°C. Proteins were resolved by 
7.5% SDS-PAGE, transferred to nitrocellulose membrane, and blotted 
using anti-pTyr antibody (4GlO). For the competition experiments, the 
GST beads were incubated with lipids (sonicated in HNE), inositol 
(1,4,5)P3 (Amersham), or inositol (1 ,3,4,5)P4 (Sigma) for 1 hr at room 
temperature prior to the addition of the cell lysates. 
Lipid Binding Assay 
[3ZP]Ptdlns (3)P, [32P]Ptdlns (3,4)Pz, and [32P]Ptdlns (3,4,5)P3 were 
prepared by incubating the precursor of these lipids with purified PI 
3-kinase in the presence of excess phosphatidylserine’as previously 
described (Carpenter et al., 1990). After 2 hr at room temperature, the 
reaction was stopped with IO mM EDTA, and lipids were isolated by 
chloroform:methanol extraction as described previously (Serunian et 
al., 1991). For the lipid selection experiments, a 200 pM solution of presonicated crude brain phosphoinositides was incubated with puri- 
fied PI 3-kinase, Ptdlns 4-kinase, and Ptdlns (4)P 5-kinase in the pres- 
ence of 15 mM HEPES (pH 7.0) 200 pM [32P]ATP (1 .I t0/mmol), and 
5 mM MgC&. The lipids were extracted with chloroform:methanol and 
dried. Dry lipids were resuspended in 10 mM HEPES (pH 7.0), 1 mM 
EDTA, sonicated, and added to 40 nl of Sepharose beads containing 
approximately 12 ng of the indicated GSTfusion protein in the absence 
or presenceof 20 mM phenyl phosphate in asolution containing 0.02% 
NP40-HNE buffer. A titration experiment has shown that at 0.02% 
NP-40 lipid binding is optimal. Incubation was carried out for 1.5 hr 
at room temperature, after which the beads were quickly washed twice 
with 1 ml of 0.5% NP-40-HNE (2-3 min total). Lipids that remained 
associated with the beads were extracted with chloroform:methanol 
(1 :I) and resolved by thin-layer chromatography (TLC) using l-propa- 
nol:2 M acetic acid (65:35 v/v). A sample of the original lipid mixture 
was also run on the TLC. The peptide competition experiments were 
done in the presence of the peptides RENEpYMPMAPQlH (pYMPM), 
EPQpYEElPlYL (pYEEI), or AEEEElYEEfEAKKKK (YEEI), as de- 
scribed above (pY indicates pTyr). The results were quantified using 
a phosphorimager (Bio-Rad). 
For the lipid selectivity experiments (Figure 5) the bound lipids 
were deacylated and analyzed by HPLC as described previously(Seru- 
nian et al., 1991). The radioactivity in each lipid was then divided by 
the radioactivity in the same lipid in the starting mixture to deter- 
mine the fraction of each lipid bound to a given SH2 domain. To com- 
pare the relative selectivities of the various SH2 domains for Ptdlns 
(3,4,5)P,, the data were normalized such that if all the lipids bound 
equally well, each would have a selectivity of I. Total radioactivity 
bound in the experiments presented is as follows: ~85, 12,473 dpm; 
~8.5 carboxy-terminal SH2,9,603 dpm; ~85 amino-terminal SH2,5,607 
dpm; Abl SH2, 2,724 dpm; Src SH2, 7,437 dpm; GST, 1,219 dpm; 
~85 SH3, 1,440 dpm; total (before SH2 selection), 11,439O dpm. The 
radioactivity from the GST and ~85 SH3 experiments did not appear 
above background in any of the phosphoinositide elution positions. 
The proportions of [32P]phosphoinositides in the starting mixture were 
as follows: Ptdlns (3)P, 39%; Ptdlns (4)P, 14.6%; Ptdlns (3,4)P2, 9.5%; 
Ptdlns (4,5)Pz, 25.5%; Ptdlns (3,4,5)P3, 11.3%. 
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